Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes.

The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond.

Boasting 20+ speakers, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery, R&D and clinical development, this event is a unique opportunity for your team to identify and target the undruggable, elevate drug design for improved target selectivity, overcome the blood brain barrier and rationalize combinations for more durable responses.

Collaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity, maximal durability to deliver the best clinical outcomes.

To know more visit: https://kinase-inhibitors-summit.com/